GNPX

Genprex, Inc. NCM · GNPX

$7.67 -0.33 (-4.12%)

Blow-off · +7.77σ Hot zone Grade B

+ Compare Open in Sniper

Mkt cap $0.0B

P/E —

Day $7.01 – $7.94

52wk $0.42 – $9.99

Avg vol 0.0M

Beta -0.91

Div yld —

Next earnings —

Quick read

Plain English

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.

GNPX last traded at $7.67, down 4.1% on the day; that's in the upper part of its 52-week range ($0.42–$9.99). Right now it's stretched well above its recent average — moves this fast often cool off or give some back.

Earnings reports are the biggest scheduled catalysts to keep an eye on, and after a strong run, watch whether the price can hold its gains on quieter days.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

KC3 upper (deep stretch), +10.37 ATR from EMA21 — no notable pattern

Long —

score 24 · tech 24 / 80 · support 0 / 20

above KC1 lower, +10.37 ATR from EMA21 · hammer

· Hammer candle — long lower wick rejection

How this grade was earned

total 24 pts

Cycle position 6

Candle signal 15

Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short B

score 45 · tech 45 / 80 · support 0 / 20

KC3 upper (deep stretch), +10.37 ATR from EMA21 · no notable pattern

ℹ️ Deep stretch (KC3): stop is set wider to avoid a whipsaw, so the reward/risk reads lower (~1R) by design — not a worse trade.

· KC3 upper stretch — deepest mean-reversion tier
· RSI hook from extreme overbought (93)
· Aligned with weak downtrend

How this grade was earned

total 45 pts

Cycle position 30

Momentum 9

Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.

Verdict

Unknown

Accounting quality Adequate

✓ More cash than debt
✓ Current ratio 3.84 (antifragile)
✓ Debt/equity 0.28 (antifragile)

⚠ Negative retained earnings

Key statistics

All statistics →

GNPX is a $4 million company, it moves more calmly than the market (beta -0.9).

Mkt cap $0.0B

P/E ttm —

Fwd P/E -3.5

Beta -0.91

Day range $7.01 – $7.94

52w range $0.42 – $9.99

Avg vol 0.0M

RSI(2) 91.7

ROE -160.8%

Net mgn —

FCF mgn —

Debt/Eq —

Div yld —

Sector Healthcare

Industry Biotechnology

Next earn —

52-week range · today's price

$0.42$9.99

More on GNPX

Earnings

See more →

Last reported: 2025-05-12
EPS (act / est): -286.00 / -451.00
Surprise: +36.6%

About

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the …